Rottendorf Pharma GmbH
NDC Database
Rottendorf Pharma GmbH
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 17
- Latest Marketing Date 2024-11-22
- Data Source FDA
- First Marketing Date 2004-08-02
Company Overview
Social Profiles
Company Snapshot
Rottendorf Pharma GmbH
Ostenfelder Str. 51-61
Germany
www.rottendorf.com/ info@rottendorf.com View on MapNDC Records ( 17 records )
Nonproprietary Name
emtricitabine and tenofovir disoproxil fumarate
Dosage Form
TABLET, FILM COATED
Strength
200; 300 mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
tamsulosin hydrochloride
Dosage Form
CAPSULE, GELATIN COATED
Strength
0.4 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TAMSULOSIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-04-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
emtricitabine, rilpivirine hydrochloride and tenofovir disoproxil fumarate
Dosage Form
TABLET, FILM COATED
Strength
200; 25; 300 mg/1; mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-08-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate
Dosage Form
TABLET
Strength
200; 25; 25 mg/1; mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tacrolimus
Dosage Form
TABLET
Strength
0.75 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TACROLIMUS
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tacrolimus
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TACROLIMUS
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tacrolimus
Dosage Form
TABLET
Strength
4 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TACROLIMUS
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
Dosage Form
TABLET
Strength
50; 200; 25 mg/1; mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
emtricitabine and tenofovir alafenamide fumarate
Dosage Form
TABLET
Strength
200; 25 mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
telmisartan and hydrochlorothiazide
Dosage Form
TABLET
Strength
25; 80 mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
telmisartan and hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 40 mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
telmisartan and hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 80 mg/1; mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
EMPAGLIFLOZIN
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMPAGLIFLOZIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-09-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
EMPAGLIFLOZIN
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMPAGLIFLOZIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-09-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lenacapavir sodium
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LENACAPAVIR SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-12-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sodium phenylbutyrate
Dosage Form
PELLET
Strength
423 mg/g
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SODIUM PHENYLBUTYRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-08-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Acoramidis hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
356 mg/1
Labeler
Rottendorf Pharma GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACORAMIDIS HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
NDC Type Breakdown
17 total- Drug for Further Processing
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
49629-010
Nonproprietary Name
emtricitabine and tenofovir disoproxil fumarate
Labeler
Rottendorf Pharma GmbH
Dosage Form
TABLET, FILM COATED
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.